Eli Lilly and Company

139.57-1.86-1.32%Vol 4 416 9421Y Perf 17.32%
Jan 17th, 2020 15:59
BID135.00 ASK140.88
Open140.88 Previous Close141.43
Pre-Market141.44 After-Market139.58
 0.01 0.01%  - -%
Target Price
144.57 
Analyst Rating
Strong Buy 1.22
Potential %
3.58 
Finscreener Ranking
★★★     49.98
Insiders Trans % 3/6/12 mo.
43/-23/-52 
Value Ranking
★★★     52.46
Insiders Value % 3/6/12 mo.
-42/-74/-90 
Growth Ranking
★★★+     55.77
Insiders Shares Cnt. % 3/6/12 mo.
-38/-72/-89 
Income Ranking
★+     39.56
Market Cap (M)134 005 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
94.09 
Earnings Date
30th Jan 2020

Today's Price Range

139.36141.74

52W Range

101.36141.97

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
1.14%
1 Month
7.79%
3 Months
28.47%
6 Months
28.83%
1 Year
17.32%
3 Years
81.26%
5 Years
102.74%
10 Years
394.70%

TickerPriceChg.Chg.%
LLY139.57-1.8600-1.32
AAPL317.812.57000.82
GOOG1 480.3928.69001.98
MSFT167.100.93000.56
XOM68.56-0.2600-0.38
WFC49.18-0.0700-0.14
JNJ149.170.97000.65
FB222.140.37000.17
GE11.81-0.0300-0.25
JPM138.200.95000.69
Financial StrengthValueIndustryS&P 500US Markets
0.70
1.20
0.81
4.64
12.90
Leverage Ratio 13.20
ProfitabilityValueIndustryS&P 500US Markets
74.60
20.20
25.20
14.10
42.10
RevenueValueIndustryS&P 500US Markets
16 205 500
16.88
-4.48
0.39
DividendsValueIndustryS&P 500US Markets
2.13
2.96
6.04
4.11
Payout ratio57.00
Earnings HistoryEstimateReportedSurprise %
Q03 20191.431.483.50
Q02 20191.461.502.74
Q01 20191.321.330.76
Q04 20181.361.33-2.21
Q03 20181.371.391.46
Q02 20181.311.5014.50
Q01 20181.131.3418.58
Q04 20171.081.145.56
Earnings Per EndEstimateRevision %Trend
12/2019 QR1.491.36Positive
12/2019 QR1.483.50Positive
12/2019 FY5.801.22Positive
12/2020 FY6.772.73Positive
Next Report Date30th Jan 2020
Estimated EPS Next Report1.49
Estimates Count4
EPS Growth Next 5 Years %11.30
Volume Overview
Volume4 416 942
Shares Outstanding (K)960 131
Trades Count32 054
Dollar Volume711 573 675
Avg. Volume3 575 435
Avg. Weekly Volume4 114 423
Avg. Monthly Volume3 354 396
Avg. Quarterly Volume3 451 078
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (88.89 %)
6 (75.00 %)
5 (55.56 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (11.11 %)
2 (25.00 %)
4 (44.44 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.22
Strong Buy
1.50
Moderate Buy
1.89

Eli Lilly and Company

Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.

CEO: David A. Ricks

Teplephone: +1 317 276-2000

Address: Lilly Corporate Center, Indianapolis 46285, IN, USA

Number of employees: 38680

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

47%53%

Bearish Bullish

48%52%

Bearish Bullish

53%47%

News

Stocktwits